Introduction
Ufo/Axl was identi®ed as the ®rst member of a new family of receptor tyrosine kinases (RTK), comprising at least three members, each of which has several names: Ufo/Axl/Ark/Tyro7, Tyro3/Sky/Rse/Brt/Tif/Dtk/Rek and Nyk/Mer/Eyk/Tyro12 (Janssen et al., 1991; O'Bryan et al., 1991; Rescigno et al., 1991; Lai and Lemke, 1991; Lai et al., 1994; Ohashi et al., 1994; Mark et al., 1994; Fujimoto and Yamamoto, 1994; Dai et al., 1994; Crosier et al., 1994; Biscardi et al., 1996; Paul et al., 1992; Graham et al., 1994; Jia and Hanafusa, 1994) . These RTKs are characterized by an unique extracellular structure, resembling neural cell adhesion molecules (i.e. two immunoglobulin-like domains juxtaposed to two ®bronectin type III-like domains). Using a transfection/tumorigenicity assay, Ufo/Axl was originally isolated from patients with chronic myeloid leukemia (O'Bryan et al., 1991) and chronic myeloproliferative disorders (Janssen et al., 1991) . First clues to the activation of the receptor came from studies of Bellosta et al. (1995) , who showed that the extracellular domain of the Ufo/Axl receptor is able to induce cell aggregation via homophilic interaction thereby inducing receptor phosphorylation. Recently, Stitt et al. (1995) and Varnum et al. (1995) reported on the identi®cation of Gas6 (growth arrest speci®c gene 6) as a ligand for Ufo/Axl, capable of speci®cally activating the receptor's intrinsic tyrosine kinase activity and initiating downstream signaling events. It has been published that Gas6 has mitogenic and survival activities for serum starved NIH3T3 ®broblasts (Goruppi et al., 1996) . Gas6 is highly homologous to protein S, a negative coregulator in the blood coagulation pathway (Man®oletti et al., 1993) . Protein S, on the other hand was identi®ed as the ligand for the Ufo/Axl related Tyro3 receptor (Stitt et al., 1995) . In contrast Godowski et al. (1995) and Ohashi et al. (1995) recently demonstrated that human Gas6 also functions as a ligand for human Tyro3, although the murine Tyro3 homologue was previously shown to interact with bovine protein S, but not with bovine Gas6 (Stitt et al., 1995) . The function of Gas6 activation of Ufo/Axl remains unclear, but its homology to protein S suggests a role in the clotting system. It was also recently proposed that one biological function of the Gas6 protein may be to initiate vascular smooth muscle cell proliferation mediated by Ca 2+ -mobilizing receptors . The fact that Ufo/Axl may be activated either through homophilic interactions or through ligand binding indicates that the regulation of this RTK is complex and dependent on its environmental context.
Tyrosine kinase receptors are transmembrane proteins composed of an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic domain harboring the tyrosine kinase activity (Ullrich and Schlessinger, 1990) . Ligand binding leads to dimerization of the receptor and autophosphorylation on tyrosines in its cytoplasmic domain. The phosphotyrosine residues then serve as docking sites for proteins that contain a common structural motif, called a src homology 2 domain (SH2) (Pawson and Pawson and Gish, 1992) . The amino acid sequences surrounding each phosphotyrosine residue, in particular the three amino acids carboxy-terminal to the phosphorylated tyrosine, determine the binding speci®city for each SH2-containing protein. Binding of a speci®c subset of these signaling molecules to the activated receptor transduces the extracellular signal to the interior of the cell and promotes biological eects, like cell proliferation or dierentiation. Fridell et al. (1996) have reported ®rst results concerning intracellular signaling of Ufo/Axl. Using an EGFR/Axl chimeric receptor they demonstrated in vivo association of the p85a subunit of phosphatidylinositol 3'-kinase with the activated Ufo/ Axl kinase. p85a appeared not to be phosphorylated and seemed dispensible for biological action. Furthermore these authors showed in vitro binding of GRB2 to the receptor and tyrosine phosphorylation of SHC although a direct association of SHC with the receptor could not be demonstrated.
By screening bacterial expression libraries with a radiolabeled tyrosine phosphorylated C-terminal fragment derived from the EGF receptor, various novel SH2 domain adaptor proteins, such as GRB2, GRB7 and GRB10 (Lowenstein et al., 1992; Margolis et al., 1992; Ooi et al., 1995) have been successfully identi®ed. This method is known as CORT for Cloning Of Receptor Targets (Skolnik et al., 1991) . We used CORT for screening a human fetal liver and a human foreskin ®broblast cDNA expression library in order to identify novel Ufo/Axl substrates. In addition to the p85a subunit of PI3-kinase, the homologous human p85b subunit, as well as phospholipase Cg1 were identi®ed as potential in vivo eectors of Ufo/Axl. Since our studies were initiated prior to the identification of Gas6 as the Ufo/Axl ligand, experiments to test these proteins as substrates were performed in intact cells overexpressing a chimeric receptor which contains the extracellular domain of the epidermal growth factor receptor (EGFR) as well as the transmembrane and kinase domains of Ufo/Axl, respectively. Previous studies have amply demonstrated the ®delity of this approach. In general, the intracellular domains are the primary determinants for the signaling pathway (Riedel et al., 1989; Seedorf et al., 1991 Seedorf et al., , 1992 . Regarding Ufo/ Axl, this approach oers advantages since it avoids complications due to cell-cell interaction or heterodimerization with another receptor. EGFR/Ufo chimeric constructs were utilized to investigate the binding anity and speci®city of various proteins containing SH2 domains. Our data showed that various receptor substrates are at least associated with the C-terminal tyrosine pY821. Two additional potential autophosphorylation sites (pY866 and pY779) may play a minor role in binding of eector proteins. Surprisingly, the results derived from coimmunoprecipitation experiments and far-Western analyses were not identical. This dissimilarity and the consequences of the multisubstrate docking site will be discussed.
Results

Expression screening for Ufo substrates
A cDNA fragment encoding the complete cytoplasmic moiety of human Ufo (amino acids 473 ± 894) linked to an N-terminal his-tag was expressed in insect cells using recombinant baculoviruses. After puri®cation and labeling, [g-32 P]autophosphorylated recombinant Ufo-His protein was used as a probe for expression library screening by the CORT strategy. We initially analysed 2 000 000 plaque forming units (pfu) from a human fetal liver lgt11 library and identi®ed 52 positive clones. However, only two of them, K45 ( Figure 1a , panel 1) and K71 ( Figure 1a , panel 2) scored positive in a secondary screen. Sequence analysis identi®ed these clones as the carboxy-terminal parts of the p85a subunit of human phosphatidylinositol 3'-kinase, containing both SH2 domains (K45) or only the C-terminal SH2 domain (K71), respectively ( Figure 1b , panels 1/2). This explains the apparently weaker hybridization signal of clone K71. In another approach, a human foreskin ®broblast library was screened with recombinant Ufo-His, since ®broblasts are known to express Ufo (O'Bryan et al., 1991) . To facilitate the identi®cation of additional Ufo eectors, these CORT analyses were performed with de®ned amounts of phage clone K45 as a positive control and p85a positive clones were identi®ed by simultaneous DNA hybridization of phage ®lters. Thus, the usage of this library revealed two additional positive clones: clone K271 containing a 900 bp insert which codes for both SH2 domains of phospholipase Cg1 (Figure 1a , b, panel 4) and clone K215 comprising 800 bp of human cDNA sequences which exhibit higher homology to the aminoterminal SH2 domain of bovine p85b than to the human p85a subunit of PI3-kinase ( Figure 1a , b, panel 3). Therefore, we concluded, that this clone represents the human p85b isoform. Full length cDNA of human p85b has been cloned and analysed (Janssen et al., manuscript in preparation) . In summary, three proteins with the potential to interact with the activated Ufo receptor were identi®ed: the p85a subunit of PI3-kinase, its homologue p85b, and PLCg.
Far-Western analysis of substrate binding
To con®rm receptor association of the eector proteins identi®ed by CORT and in order to detect other putative receptor targets, in vitro binding studies with GST fusion proteins of various RTK substrates were performed. cDNA obtained by CORT as well as c-src-SH2 and complete GRB2 were bacterially expressed as GST fusion proteins. In addition, puri®ed GST-lck-SH2 and GST-lck-SH3 fusion proteins were used. Puri®ed lck or crude lysates all of which contained roughly equal amounts of GST fusion proteins, were electrophoresed and transferred onto nitrocellulose. In analogy to the CORT assay, Ufo-His was autophosphorylated in vitro with [g-32 P]ATP and used to demonstrate speci®c interaction. In this far-Western analysis, all the substrates identi®ed by CORT as well as GRB2, lck-SH2 and c-src-SH2 were directly bound by recombinant cytoplasmic Ufo-His (Figure 2a , lanes 1 ± 6), whereas no speci®c binding could be observed with lck-SH3 (Figure 2a ± d, lanes 7) . In order to identify putative receptor binding sites of these eectors, synthetic phosphopeptides corresponding to potential Ufo autophosphorylation sites were used in a competition assay. Filters with immobilized GST fusion proteins were preincubated with 50 mM each of dierent phosphopeptides. Incubation of ®lters with radioactively labeled Ufo-His was performed as described above. Binding of cytoplasmic Ufo-His to GST-PLCg-SH2-SH2 (Figure 2a (Figure 2d , lanes 2 and 3) compared to the control ®lter ( Figure  2a, lanes 2 and 3) . However, blocking with either phosphopeptide pY779 (DGLpYALMSRC) or pY821 (EILpYVNMDEG) (Figure 2b , c, lanes 2 and 3), comprising consensus binding sites for p85a (YXXM; Songyang et al., 1993) , resulted in a drastic reduction in signal strength as compared to the control ( Figure  2a ). These data indicate that tyrosines 779 and 821 of the Ufo receptor may act separately or in concert as binding sites for both p85 isoforms. Figure 2c (lane 4) shows that inhibition of GRB2 binding was almost completely achieved by competition with peptide pY821, whereas phosphopeptides pY779 and pY866 (Figure 2b , d, lane 4) did not show any inhibiting eect on GRB2 binding. Therefore, binding of GRB2 was con®ned to tyrosine 821, as suggested earlier by Fridell et al. (1996) , who achieved inhibition of GRB2 binding in vitro by a 821 ± 824 deletion mutant.
Recently, c-src was identi®ed as an eector for the Ufo family RTK sky/TyRo3 .
For this reason, we tested whether cytoplasmic tyrosine kinases of the src family, namely lck and csrc could serve as Ufo substrates in vitro. Ufo-His bound speci®cally to GST-lck-SH2 (Figure 2a To obtain more conclusive data, we decided to use a mutagenesis strategy to determine c-src binding speci®city.
So far, our analyses demonstrated that tyrosine 821 and its surrounding amino acid context at the Cterminus of human Ufo apparently serves as a multisubstrate binding site at least for the two homologous p85 proteins, GRB2, PLCg and lck. Additionally, tyrosines 866 and 779, also located at the Ufo Cterminus, may allow further binding for PLCg and the p85 proteins, respectively.
Generation of an EGFR/Ufo chimera
Up to this point our studies were performed with cytoplasmic Ufo-His which was autophosphorylated in vitro. To obtain further proof for substrate binding, we generated a receptor chimera using the extracellular domains of the EGF receptor, fused to the transmembrane and intracellular moiety of the Ufo receptor. In order to ensure exact transition points without the need to generate additional restriction sites, we performed a one-tube based PCR protocol (Cao, 1990; PontKingdon, 1994; Sarkar and Sommer, 1990 
Far-Western competition analysis of dierent SH2 containing GST fusion proteins with 32 P-labeled Ufo-His and Ufo derived phosphopeptides. Bacterial lysates containing approximately 2 mg of GST-PLCg-SH2-SH2 (lane 1), GST-p85a-SH2-SH2 (lane 2), GST-p85b-N-SH2 (lane 3), GST-GRB2 (lane 4), GST-c-src-SH2 (lane 6), as well as 2 mg of puri®ed GST fusion proteins of lck-SH2 (lane 5) and lck-SH3 (lane 7) were separated on 10% polyacrylamide gels and blotted onto nitrocellulose. Following blocking, ®lters were preincubated without peptide (a) or 50 mM of Ufo derived peptides pY779 (b), pY821 (c) or pY866 (d), respectively. After 4 h, puri®ed 32 P-labeled Ufo-His was added and incubated overnight. Finally, ®lters were washed and autoradiographed. Due to protein degradation in bacteria, lanes 2 and 3 showed more than one band, the largest band corresponding to the mature protein. Lanes 6 ± 7 show a threefold longer exposure compared to lanes 1 ± 5 antibodies. Figure 3a clearly demonstrates EGF dependent tyrosine phosphorylation of the chimeric receptor and concomitant substrate phosphorylation. Prominent phosphorylated proteins appeared with apparent molecular weights of about 84 kDa, 70 kDa and 45 kDa. Especially the 84 kDa and 45 kDa proteins were clearly phosphorylated on tyrosine in response to EGF stimulation. Reprobing with anti-Ufo antibodies con®rmed the chimeric nature of the precipitated receptors (Figure 3c ). A comparison of NIH3T3/2.2 cells overexpressing either equal amounts of wildtype EGFR or EGFR/Ufo chimeric receptors showed a dramatic dierence in tyrosine autophosphorylation levels after EGF stimulation. EGFR overexpressing NIH3T3/2.2 cells showed substantially higher levels of tyrosine phosphorylation of both EGFR and cellular proteins, suggesting that the Ufo receptor possesses an inherent weak kinase activity (data not shown).
To demonstrate in vivo association of the substrates identi®ed by our in vitro binding assays, chimeric receptors were immunoprecipitated from the stable cell lines using anti-EGFR antibodies, blotted onto nitrocellulose and probed with antibodies against PLCg, p85a/b (lacking isoform speci®city), c-src and GRB2. Our results clearly demonstrate an activation dependent association of EGFR/Ufo with p85a and/or p85b (Figure 3b ), whereas speci®c interaction with PLCg, c-src or GRB2 could not be demonstrated. Since both bands detected with anti-phosphotyrosine and anti-p85 antibodies can be superimposed exactly, we propose that p85 (a and/or b) become(s) phosphorylated upon receptor activation. The fact that only p85 binding could be detected may be due to lower substrate expression levels and/or lower binding anities respective to Ufo of PLCg, c-src and GRB2.
Transient expression of wildtype and mutant receptor chimeras
To achieve higher detection sensitivities and to overcome putative substrate competition, we switched to transient transfection assays in human embryonic kidney 293 cells. After transfection these cells show very high expression levels of the EGFR/Ufo chimera and possess a low background of endogenous EGFR. Moreover, cotransfection and concomitant high overexpression of receptor substrates enabled us to distinguish between p85a and p85b binding. In addition, it was possible to test other eectors, such as lck which are not expressed in these cells endogenously. Unfortunately, cells not stimulated with EGF showed considerable receptor autophosphorylation due to the high receptor density on the cell surface, preventing their use as negative controls (data not shown).
In an eort to speci®cally abrogate binding of Ufo substrates in vitro and in vivo, we performed in vitro mutagenesis of the EGFR/Ufo receptor chimera (see Figure 4 ). Tyrosines 779, 821 and 866 were each substituted for phenylalanine. Additionally, combina- (Figure 2d ), tyrosine 866 seems to be of minor importance in binding PLCg when compared to tyrosine 821. Probing with p85a and p85b GST fusions ( Figure  5c , d), respectively, also con®rmed direct binding to in vivo autophosphorylated wildtype EGFR/Ufo (lane 2). Tyrosine 821 again was identi®ed as the main binding site for p85 proteins. In contrast to PLCg, the mutation of tyrosine 821 or 821 plus 866 (lanes 4 and 7) could not abrogate binding of p85a-SH2-SH2 completely, since a faint band could be observed after longer exposures (not shown). Complete inhibition of p85a binding could only be observed using mutant 779/821 YY-FF. With GST-p85b-N-SH2 this eect could not be observed. Nevertheless tyrosine 821 appears to be the major binding site for both p85 proteins, since the mutation of tyrosine 779 (Y-F) alone had little if any eect on p85 binding to EGFR/Ufo (Figure 5c , d, lane 3). As expected, binding of p85 was also impaired when using mutant 824 M-I, where methionine at +3 respective to tyrosine 821 was changed to isoleucine (Figure 5c, d, lane 9) . GST-p85a-SH2-SH2 showed a weak band, demonstrating that isoleucine could substitute for methionine, at least to some extent. As suggested by these data, substituting tyrosine 821 with phenylalanine, rather than methionine on +3 with isoleucine, has a more drastic eect on p85 binding. Our results con®rm the binding consensus pYXXM for both human p85a and human p85b, as described by Songyang et al. (1993) .
Using GST-GRB2 as a probe (Figure 5e ), our farWestern analysis again demonstrated association of GRB2 with its consensus binding site tyrosine 821 (pYVNM). This direct interaction was clearly phosphotyrosine dependent, since no binding could be observed with the non-autophosphorylated kinaseinactive mutant (Figure 5e As expected, GST-c-src-SH2 also bound to activated wildtype EGFR/Ufo (Figure 5f , lane 2). Interestingly, c-src-SH2 showed the same binding characteristics as GRB2, except for mutant 823 N-Q, which in contrast to GRB2 did not show any reduced binding in this case Similar experiments were performed using the p85a or p85b subunits of PI3-kinase (Figure 6b and c) , Figure 2) , where tyrosines 779 and 821 both contributed to p85 binding, these coprecipitation data show that tyrosine 821 is necessary and is, in fact, sucient on its own for p85 binding. The possibility that tyrosine 779 could represent an additional, perhaps functionally relevant low anity binding site for p85 proteins is currently under investigation.
Coprecipitation experiments of wildtype and mutant receptor chimeras with GRB2 ( Figure 6d Even binding of the kinase negative mutant of EGFR/ Ufo still occurred to some extent (lane 1). No GRB2 coprecipitation with anti-Ufo antibodies could be observed in control cells where no chimeric receptor was coexpressed (lane 10), thus showing that the observed eect is not due to the endogenous Ufo background of 293 cells. These results suggest that indirect, possibly phosphotyrosine independent binding sites for GRB2 must exist on the receptor in addition to tyrosine 821, the main direct binding site for GRB2 (see Figures 2e and 5e) . One of these additional bindings of GRB2 may normally occur via SHC, thus linking SHC via GRB2 and SOS to the RAS-pathway. We were able to coimmunoprecipitate SHC with EGFR/Ufo in a transient expression system; however no association with SHC in direct binding assays was observed (data not shown). This is in accordance with the data of Fridell et al. (1996) , who reported on SHC phosphorylation and concomitant GRB2 binding after EGFR/Ufo stimulation, but were not able to demonstrate direct binding of SHC to the receptor.
When c-src or lck were coexpressed together with EGFR/Ufo and subsequently precipitated with anti-EGFR antibodies or anti-Ufo antibodies (Figure 6e, f) , it was observed that c-src or lck binding to the receptor could not be abrogated by any of the mutants used in this assay. No coprecipitation with anti-EGFR or antiUfo antibodies was observed when c-src or lck were expressed without EGFR/Ufo (lane 10). These results seem to contradict our previous in vitro data, where tyrosine 821 and its amino acid context de®ned speci®c binding of GST-c-src-SH2 or GST-lck-SH2 (Figure 5f , g). However, coexpression analysis was performed with full length c-src and full length lck. Therefore, one could speculate that complete c-src or lck, respectively, may use additional, non-SH2 binding sites on the receptor in vivo, at least under conditions of high overexpression. We currently try to determine whether protein domains other than SH2 are involved in this interaction.
Discussion
Various strategies were applied to examine the signals engaged by Ufo. The his-tagged cytoplasmic moiety of Ufo (Ufo-His) was used in the CORT method as à bait' to identify growth factor receptor binding proteins. Human fetal liver and human foreskin ®broblast libraries were screened and we were able to isolate four positive cDNA clones. Two clones, representing the C-terminal SH2 domain and N-and C-terminal SH2 domains of the p85a subunit of PI3-kinase, were isolated from a human fetal liver cDNA library, whereas two other clones, one representing the N-terminal SH2 domain of p85b and the other encompassing two SH2 domains of phospholipase Cg1, were obtained from a human foreskin ®broblast cDNA pool. However, substrates with a somewhat lower anity to Ufo and/or a lower expression level would not have been identi®ed in this screening procedure. Using the same Ufo-His probe and immobilized GST-fusions of the protein modules isolated via CORT in a blot overlay assay, we were able to con®rm our CORT data in vitro by demonstrating direct receptor-substrate interactions of PLCg-SH2-SH2, as well as p85a-SH2-SH2 and p85b-N-SH2. In addition, binding of GST-GRB2, GST-csrc-SH2 and GST-lck-SH2 was detected in this assay. Speci®c competition was achieved using tyrosine phosphorylated synthetic peptides derived from the human Ufo protein and proved that phosphopeptide pY821 (EILpYVNMDEG) inhibited binding of all receptor eectors examined, except for c-src. These data emphasize the outstanding importance of tyrosine 821 of human Ufo in substrate binding. By using phosphopeptides pY779 (DGLpYALMSRC) and pY866 (AGRpYVLCPST), speci®c inhibition of p85 proteins (pY779) and PLCg (pY866), respectively, was also achieved, suggesting that these binding sites of Ufo may be occupied by substrate SH2 domains as well.
Direct receptor binding to in vivo autophosphorylated EGFR/Ufo receptor chimeras was demonstrated in another assay. Chimeric receptors were transiently overexpressed in 293 cells and isolated by immunoprecipitation. Immobilized EGFR/Ufo receptor chimeras were incubated with GST fusion proteins containing the SH2 domains of various eectors and speci®c binding was demonstrated using anti-GST antibodies. Thus, direct binding of PLCg, p85 proteins, GRB2, csrc and lck to in vivo autophosphorylated EGFR/Ufo was shown. By using tyrosine to phenylalanine point mutants of chimeric EGFR/Ufo, SH2 binding sites of these eectors were determined. To summarize, our in vitro data, using in vitro autophosphorylated Ufo-His protein or chimeric EGFR/Ufo expressed in 293 cells clearly showed that tyrosine 821 (EILpYVNM) of human Ufo serves as a highly¯exible, multi-substrate docking site for at least p85a/b proteins, phospholipase Cg1, GRB2, c-src and lck.
GRB2 binding through tyrosine 821 is in accordance with predictions obtained from phosphopeptide inhibition studies, since a consensus asparagine is located at position +2 relative to the tyrosine (Songyang et al., 1993) . Fridell et al. (1996) also observed GRB2 in vitro binding to tyrosine 821 of human Ufo.
The context of tyrosines 779 (pYALM) and 821 (pYVNM) ®ts the optimal binding consensus for p85a-SH2 domains (methionine at +3 respective to phosphotyrosine) as predicted by Songyang et al. (1993) . No substantial dierence in binding characteristics was observed between p85a and the human p85b homologue of p85a, implying that both p85 proteins have the same binding consensus with an obligatory methionine at position +3 respective to tyrosine. As predicted, 50 mM each of phosphopeptides pY821 and pY779 speci®cally blocked binding of Ufo-His to immobilized GST fusion proteins of p85a-SH2-SH2 and p85b-N-SH2 (see Figure 2b) . However, in our in vivo model system using 293 cells (Figure 6 ), a receptor mutant with tyrosine 779 mutated to phenylalanine coprecipitated both p85a and p85b comparable to wildtype EGFR/Ufo, whereas only a Y-F mutation at tyrosine 821 resulted in a complete loss of p85 binding (see Figure 6b and c) . Similar results were presented by Fridell et al. (1996) , who observed complete inhibition of p85a binding in vivo by using an EAK (EGFR/Axl kinase) chimera with a 821 ± 824 deletion. In addition, these results correspond closely to our in vitro data, where immobilized wildtype and mutant EGFR/Ufo were incubated with GST-p85 fusion proteins ( Figure  5c, d) . On longer exposures, however, a faint band appeared with mutant 821 Y-F that was incubated with GST-p85a-SH2-SH2, whereas no such band was visible with the double mutant 779/821 YY-FF. We conclude that binding of p85 proteins to tyrosine 779 and its amino acid context can occur to some extent, perhaps also in vivo, but with an anity greatly reduced in comparison to tyrosine 821. It must also be considered that tyrosine 779 is located towards the end of ± but still within ± the tyrosine kinase domain. Both tyrosine 779 and methionine 782 are conserved in many tyrosine kinases (Hanks et al., 1988) and the corresponding Y1313 of the Met RTK is not involved in association of signaling molecules (Ponzetto et al., 1993) . In contrast, Biscardi et al. (1996) propose that the corresponding position in the Rek receptor, another member of the Ufo/Axl family, may function as a potential binding site for the p85 subunit of PI3-kinase, especially as a tyrosine 821-like binding site for p85 is not present in this receptor. An interesting article by Stover et al. (1995) demonstrated that two tyrosines (Y891 and Y920), located in the kinase domain of the EGF receptor are tyrosine phosphorylated by src and may function as an interaction site for src and p85a, respectively. The latter site corresponds to tyrosine 779 of the Ufo/Axl receptor. Using tyrosine 779 as a low anity docking site for the second SH2 domain of p85 proteins could be of functional signi®cance, since various research groups have shown that simultaneous binding of two SH2 domains is required for full activation of PI3-kinase activity (Rordorf-Nikolic et al., 1995; Herbst et al., 1994; Carpenter et al., 1993) . Determination of PI3-kinase activity associated with the respective receptor mutants may resolve this issue. This will be addressed in further studies. In contrast to p85a and GRB2 binding, direct association of PLCg, c-src and lck would not have been predicted unequivocally from published data that were obtained by binding studies with degenerate phosphopeptide libraries. In some cases, peptide studies may not provide accurate estimates of SH2 binding speci®city since synthetic peptides may not mimic all the structural features of SH2 binding sites on autophosphorylated receptors. In fact, this may be particularly true for PLCg and src family members where it has been shown that binding is not determined solely by the three amino acids carboxy-terminal to the phosphorylated tyrosine (Alonso et al., 1995; Songyang et al., 1995; Pascal et al., 1994; Larose et al., 1995) . The optimal sequence carboxy-terminal to phosphotyrosine that binds to the src SH2 domain has been determined from a library of phosphopeptides and was found to be pYEEI. The selectivity of the src SH2 domain was highest for a large aliphatic amino acid at position +3, with slightly lower selections at positions +1 and +2 (Songyang et al., 1995) . The residues carboxy-terminal to tyrosine 821 (EiLpYVNMD) of the Ufo receptor, match this sequence at the +2 and +3 positions. The application of a phosphopeptide competition binding assay by Alonso et al. (1995) underscored the importance of an aspartic acid residue at position +4. A similar study demonstrated the relevance of a glutamic acid at position 73 or 74 with respect to phosphotyrosine (Bibbins et al., 1993) . In fact, in the case of the Ufo RTK both amino acids are found at these positions.
The presence of two SH2 domains in the PLCg protein suggests a mechanism of stimulating its enzymatic activity by simultaneous binding of both SH2 domains to the receptor. Indeed, in vitro analyses (Figure 2c, d and Figure 5b ) and coimmunoprecipitation assays (Figure 6a ) indicate the importance of tyrosine 821 in conjunction with tyrosine 866 for PLCg binding. As for the p85 proteins, position Y821 is used preferentially. Using phosphopeptides for binding, the SH2 domains of phospholipase C-g1 select hydrophobic residues at both the +1 and +3 positions (Songyang et al., 1993) . This selectivity is consistent with the residues carboxy-terminal of Ufo Y821 (pYVNM). The PLCg domain speci®city also seems to include amino acids in position +4, +5 and +6, as well as residues N-terminal relative to phosphotyrosine (Pascal et al., 1994; Larose et al., 1993 Larose et al., , 1995 Eriksson et al., 1995) . A comparison between the amino acid sequences surrounding the phosphorylated tyrosine residues involved in binding of PLCg to the Ufo receptor, and various other receptors, i.e. EGF receptor, FGF receptor-1, PDGF a and b receptor, HGF receptor and NGF receptor, failed to produce a conclusive picture of the binding preference for this SH2 eector molecule.
By stable transfection of NIH3T3/2.2 cells with EGFR/Ufo, we were able to demonstrate EGF dependent autophosphorylation of the receptor and concomitant tyrosine phosphorylation of a speci®c set of intracellular substrates, including prominent bands with estimated molecular weights of 84 and 45 kDa, respectively (Figure 3a) . However, compared to the EGFR, the Ufo receptor possesses a very low autophosphorylation activity (data not shown). Of the eectors identi®ed by our in vitro assays, only p85a and/or p85b association with the activated receptor could be demonstrated in these stably transfected cells (Figure 3b) . Fridell et al. (1996) , who used Gas6 to speci®cally stimulate Ufo in stably transfected 32D cells, obtained similar results, as activation dependent PI3-kinase activity could be measured, whereas no GRB2 association to the receptor could be observed. Since our results strongly suggest that various SH2 eectors bind to an identical multi-substrate docking site (pY821) on the Ufo RTK, these observations can be explained by competition between dierent substrates. We suggest that substrate binding is dependent on its local concentration and its anity for the Ufo receptor. Under the experimental conditions used, p85a and/or p85b were obviously the preferred eectors binding to the multi-substrate docking site at tyrosine 821. We have investigated Ufo substrate binding in dierent assays using in vitro and in vivo model systems with each assay underlying its special limitations. We found that our in vitro data provided a clear picture of direct, phosphotyrosine dependent SH2 interactions. By testing receptor substrate interactions in vivo, we learned that Ufo signaling is much more complex. In vivo, multiple secondary interactions as well as competition for binding sites occur. While the association of the p85 proteins to EGFR/Ufo chimeras harboring mutations at their speci®c binding site was completely abolished in our coimmunoprecipitation assays, GRB2, PLCg, c-src and lck showed additional interactions. GRB2 and PLCg showed reduced, but not completely abrogated in vivo binding when the respective binding site mutants were applied. Additionally, c-src and lck coprecipitation did not seem to be in¯uenced at all by any of the mutants. Even binding to kinase-inactive EGFR/Ufo occurred. We conclude, that these observations may result from secondary interactions, such as binding of GRB2 via SHC and/or phosphotyrosine independent binding. The latter has been observed in several cases recently (HolgadoMadruga et al., 1996; Galcheva-Gargova et al., 1996; Wu et al., 1996; Castagnino et al., 1995; Durick et al., 1996; Charest et al., 1996) . Other protein domains of the respective receptor substrates could be involved in the interaction as well. Since all of these proteins also contain SH3 domains, these modules together with the SH2 domains could be involved in binding interactions directly with the receptor or between dierent eectors. It should be taken into consideration that the high protein amounts used in this assay do not re¯ect physiological conditions and may in¯uence the data obtained. With respect to c-src and lck, it is noteworthy that a recent report showed evidence that c-src can phosphorylate the EGF receptor on novel sites, creating additional sites for SH2 binding (Stover et al., 1995) . Coexpression analyses of c-src or lck together with a kinase-inactive EGFR/Ufo chimera indeed revealed tyrosine phosphorylation of the receptor (unpublished data), thus providing an alternative explanation for our in vivo data concerning both the c-src and lck proteins. Further studies with EGFR/ Ufo and c-src or lck mutants should help to elucidate the role of the various sites and domains in Ufo signaling. In order to understand the importance of the individual Ufo docking proteins identi®ed in this report, the respective anities of the substrates for the multi-docking site, their relative abundance in the cell, as well as spatial and temporal limitations of substrate binding should be taken into account. This multi-substrate docking site in the Ufo receptor shows a strong resemblance to the`multifunctional docking site' described for the hepatocyte growth factor (HGF) receptor (met) family (Ponzetto et al., 1994) and implies a similar mechanism for signal transduction in both receptor families.
Materials and methods
Antibodies and growth factors
The following antibodies were purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany): Anti-phospholipase Cg1 (sc-426), anti-phosphotyrosine (PY20), anti-GRB2 (sc-503, sc-255), anti-PI3-kinase (sc-423), anti-GST (sc-138), anti-c-src (sc-19) and anti-lck (sc-433 
Baculovirus methods
The baculovirus system was used to express and isolate an Ufo polypeptide spanning the complete intracellular moiety of the receptor (amino acids 473 ± 894). In order to introduce a suitable restriction site at the intracellular membrane transition point, standard PCR was performed with Taq-polymerase (Perkin-Elmer; Langen, Germany), using sense primer Ufo-BamHI (5'-CGCGGATCCG-CACCGGCGAAAGAAGGAGAC-3'), Ufo antisense primer D (5'-CCCAGGCTGTTCAAGGTAG-3') and human Ufo cDNA (Janssen et al., 1991) as a template. The PCR product was puri®ed and ligated into pMOSBlue T-vector (Amersham; Braunschweig, Germany). After veri®cation of the DNA sequence the PCR fragment was cut out using BamHI and KpnI and ligated together with a 1221 bp KpnI-BamHI fragment of human Ufo cDNA in BamHI digested and dephosphorylated pBlueBacHisB baculovirus transfer vector (Invitrogen Corp; Leek, The Netherlands). Restriction analysis and dideoxy sequencing con®rmed the identity of the construct. The vector pBlueBacHisB provides the expressed protein with a his-tag consisting of ®ve consecutive histidines, allowing easy anity puri®cation by Ni 2+ -chelate anity chromatography. Using a Lipofectin based linear transfection module (Invitrogen Corp.), DNA of this construct was cotransfected together with linearized baculovirus DNA into SF9 insect cells, in accordance with the supplier's instructions.
For large scale puri®cation of recombinant Ufo-His protein, 6610 7 HF-cells were infected with recombinant viral stocks (multiplicity of infection 20) and incubated at 278C for 48 h. The cells were collected, washed in PBS and resuspended in 3 ml of 20 mM Tris/Cl, pH 8.0, 1% NP-40, 100 mg/ml phenylmethylsulfonyl¯uoride (PMSF), 1 mg/ml pepstatin and 0.5 mg/ml leupeptin. After sonication for 20 s and centrifugation (10 min, 20 000 g), the supernatant was diluted in another volume of 1 M NaCl, 40 mM Naphosphate, pH 7.9. Ufo-His was precipitated for 2 h with 150 ml/ml lysate of a 50% suspension of Ni 2+ -NTA-Agarose (Qiagen) on ice with continuous agitation. Beads were washed 12 times with 20 mM Na-phosphate, pH 6.0, 500 mM NaCl, supplemented with 10 to 40 mM imidazole to increase wash stringency. Elution of bound protein was performed with SDS running buer (50 mM Tris, pH 6.8, 2% SDS, 0.1% Bromphenolblue, 10% glycerol, 100 mM DTT). Radioactive labeling of Ufo-His was performed with 1 mg of puri®ed, Ni 2+ -NTA bound protein and 150 mCi [g-32 P]ATP in OLP buer (22 mM HEPES, pH 7.4, 4.4 mM MnCl 2 , 27.5 mM MgCl 2 , 0.1 mM Na 3 VO 4 , 1 mM DTT) (Olivier et al., 1993) . After four to six washes with PBS, labeled protein was eluted with 500 mM imidazole in PBS/1 mM Na 3 VO 4 .
Screening of expression libraries
Screening of lgt11 expression libraries was performed using the CORT procedure (Skolnik et al., 1991; Ayer et al., 1993; Singh et al., 1988) . lgt11 libraries, constructed from human fetal liver and human foreskin ®broblast cDNA were obtained from Clontech Laboratories Inc. (Heidelberg, Germany). lgt11 phages were plated at a density of 8610 4 plaques per 13.5 cm culture plate. Incubation of the plates was done at 428C until tiny plaques became visible. The plates were overlaid with nitrocellulose ®lters impregnated with 10 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and incubated overnight at 378C. Filters were removed and blocked in 5% Carnation dry milk, 20 mM HEPES, pH 7.5, 50 mM KCl, 10 mM MgCl 2 , 10 mM b-glycerophosphate, 1 mM dithiothreitol (DTT) and 0.1% Nonidet P-40 (NP-40) for 10 to 12 h at 48C. Following blocking, in vitro [g-32 P]-autophosphorylated Ufo-His protein was added (speci®c activity 10 7 d.p.m./mg of protein) and incubated overnight in 1% Carnation dry milk, 20 mM HEPES, pH 7.5, 50 mM KCl, 10 mM MgCl 2 , 10 mM b-glycerophosphate, 10 mM DTT, 10% glycerol and 0.1% NP-40. Filters were washed once in PBS, 0.2% Triton X-100 for 10 min at 48C and three times in PBS, 0.2% Triton X-100, 100 mM KCl for 10 to 15 min at 48C. Dried ®lters were exposed to X-OMAT DS (Eastman Kodak Corporation; Rochester, NY) for 6 to 12 h at 7708C. Positive areas were picked and plaque puri®ed. Resulting positive phages were isolated and cDNA was analysed after subcloning into the pT7T3/19U plasmid vector (Pharmacia).
Generation of EGFR/Ufo chimera and site-directed mutagenesis
Chimeric EGFR/Ufo cDNA was constructed using a onetube based`megaprimer' PCR approach (Cao, 1990; PontKingdon, 1994; Sarkar and Sommer, 1990) . The templates were complete human Ufo cDNA (Janssen et al., 1991) in pSP64 and complete human EGFR cDNA (Ullrich et al., 1984) in pCMVneo. Three oligonucleotide primers were used: EGFR sense primer C (5'-CGGGACTGCGTCTCT-TGCC-3', 100 pmoles), Ufo antisense primer D (5'-CCCAGGCTGTTCAAGGTAG-3', 100 pmoles) and bridging primer B (5'-CCTAGCAGTACATACCACCAG-GACGGGATCTTAGGCCC-3', 0.5 pmoles). Primer B is a chimeric antisense primer containing sequences of the extracellular region of EGFR precisely joined to the transmembrane region of the Ufo receptor. PCR was performed under standard conditions using Taq-polymerase (Perkin-Elmer). The ampli®ed cDNA was cloned into pMOSBlue T-vector (Amersham; Braunschweig, Germany) and veri®ed by DNA sequencing. A NaeI/KpnI fragment of the chimeric EGFR/Ufo cDNA was ligated together with a ClaI/NaeI fragment of EGFR-cDNA (pCMVneo) and a KpnI/XbaI fragment of Ufo-cDNA (pSP64) into pCMVneo. The integrity of expression vectors containing full length chimeric cDNA was con®rmed by DNA sequencing. For mutagenesis, the Transformer site-directed mutagenesis kit (Clontech Laboratories; Heidelberg, Germany) was used with pCMVneo ± EGFR/Ufo serving as a template. Elimination of a unique SalI site allowed for selection of successfully mutated plasmids. 
Expression vectors for Ufo substrates
The complete human p85a subunit of PI3-kinase and the homologous human p85b cDNA were isolated from a lgt11 fetal liver cDNA library and subcloned into EcoRI digested pcDNA3 expression vector (Invitrogen) (Janssen et al., manuscript in preparation) . Human PLCg cDNA (lacking ®ve aminoterminal amino acids; Burgess et al., 1990) in pRK5 expression vector was described earlier (Herbst et al., 1991) . Complete mouse GRB2 cDNA (Suen et al., 1993) in pRSVH20 expression vector was a gift from JL Bos and chicken c-src cDNA (Takeya and Hanafusa, 1983 ) in pMT2 expression vector was provided by Linda
Smit. An EcoRI fragment of complete human lck cDNA (Perlmutter et al., 1988) was kindly provided by R Perlmutter and subcloned into EcoRI digested pcDNA3.
Transient transfection of 293 cells
293 cells were transiently transfected as described (Chen and Okayama, 1987) . For cotransfection experiments, a receptor vs substrate ratio of 1 : 3 was used. After stimulation with EGF (75 ng/ml) for 5 min, cells were lysed in 200 ml of ice cold lysis buer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 10% glycerol, 100 mM NaF, 10 mM Na 4 P 2 O 7 , 0.1 mM NaMoO 4 , 1 mM Na 3 VO 4 , 1 mM PMSF and 10 mg/ml Aprotinin). The lysates were cleared by centrifugation (5 min, 20 000 g), followed by immunoprecipitation with 3 mg of speci®c antibody and 25 ml of a 50% suspension of Protein G Sepharose CL-4B (Pharmacia) for 2 h at 48C. The beads were washed three times with HNTG-buer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol, 10 mM NaF, 1 mM Na 3 VO 4 ) and eluted in 25 ml 26SDS running buer.
Generation of stable cell lines
Stable cell lines were generated using retrovirus mediated gene transfer (Pear et al., 1993) . The pCMVneo EGFR/ Ufo vector was digested with MscI and HpaI and the resulting EGFR/Ufo cDNA fragment was blunt-end ligated in HpaI digested and dephosphorylated pLXSN vector (Miller and Rosman, 1989) . pLXSN-EGFR/Ufo was transfected in BOSC 23 cells cultured on 10 cm dishes using the transfection procedure as outlined above. Fifteen hours after transfection, cells were washed with PBS and cultured for a further 24 h in 4 ml DMEM/F12/10% FCS. Tissue culture media were removed and ®ltered through 0.2 mm sterile ®lters. Two ml of retrovirus suspensions with 8 ng/ml polybrene (Sigma; Munich, Germany) were used to infect &1610 6 NIH3T3/clone 2.2. cells. After 24 h, media were replaced by DMEM/10% FCS and cultured for another 24 h. In an eort to select transfected clones, cells were trypsinized and seeded at various densities in DMEM supplemented with 10% FCS and 0.6 mg/ml Geneticin. Clonal cell populations were isolated, expanded and tested for receptor expression by immunoblot.
Immunoblotting
Proteins were resolved by 8 or 10% SDS ± PAGE and blotted onto nitrocellulose. Filters were blocked with NET/ G buer (50 mM Tris/Cl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.05% Triton X-100, 0.25% gelatine) for 2 h at room temperature. Speci®c antibodies were added at 1 mg/ ml in NET/G and incubated overnight at 48C. Following incubation with horseradish peroxidase conjugated secondary goat anti mouse or rabbit antibodies, respectively, ®lters were developed with ECL reagent (Amersham Inc.; Braunschweig, Germany). For reprobing purposes, ®lters were incubated in stripping buer (62.5 mM Tris, pH 6.8, 2% SDS, 100 mM b-mercaptoethanol) for 30 ± 45 min at 508C, washed with H 2 O, blocked and probed as described above.
GST fusion proteins and far-Western blotting cDNA of various potential Ufo eectors were bacterially expressed as glutathion S-transferase (GST) fusion proteins. cDNA isolated by CORT, namely p85a-SH2-SH2 (amino acids 303 ± 724) and PLCg-SH2-SH2 (amino acids 517 ± 792) was digested with EcoRI and cloned into pGEX-4T1 (Pharmacia). p85b-N-SH2 (amino acids 107 ± 652) cDNA was obtained from a human fetal liver cDNA library, digested with EcoRI and cloned into pGEX-4T1. Human GRB2 full length cDNA and chicken c-src-SH2 (amino acids 146 ± 242) were ampli®ed using gene speci®c primers (GRB2 sense, 5'-CGGGATCCCGGGAAGC-CATCGCCAAATATG-3'; GRB2 reverse, 5'CGGAAT-TCCGATTGCTTCTTGACTCTTAGACG-3'; c-src sense, 5' -CGG AATTCTGG TACT TTGGGA AGATC ACTC-3'; c-src reverse, 5'-CGGAATTCGACGTTGGTCAGGCGG-TGG-3'), cut with BamHI and EcoRI or EcoRI only, and cloned into pGEX-4T1 (Pharmacia). Puri®ed lck-SH2 (amino acids 120 ± 226) and lck-SH3 (amino acids 54 ± 120) were obtained from Santa Cruz Biotechnology Inc. For phosphopeptide competition experiments, bacteria expressing GST fusion proteins were lysed in SDS running buer and analysed by SDS ± PAGE. For other applications, cell lysates were prepared as described (van der Geer et al., 1995) . Before incubating with nitrocellulose ®lters, crude lysates were diluted in 10 mM Tris/Cl pH 7.4, 150 mM NaCl, 0.2% Tween 20 (TBST) to approximately 1 mg/ml of GST fusion proteins. Filters were blocked for 2 h with 5% BSA in TBST. After incubation with bacterial lysates (1 h, 48C), ®lters were washed twice with TBST and twice with 10 mM Tris/Cl pH 7.4, 150 mM NaCl (TBS). Detection of GST fusion proteins was performed with anti-GST monoclonal antibodies followed by incubation with horseradish peroxidase conjugated secondary antibodies. Blots were developed as described above. In case of high background levels, crude lysates were puri®ed using glutathione sepharose 4B (Pharmacia). GST fusion proteins were allowed to bind for 1 h at 48C, washed three times with PBS and eluted with freshly prepared 5 mM reduced glutathione in 50 mM Tris, pH 8.0.
Phosphopeptide competition experiments
